Proactive Investors - Run By Investors For Investors

Outlook Therapeutics stock triples in three days after Oppenheimer offers $12 price target

Analysts at Oppenheimer saw potential in the development of its ONS-5010 treatment for various eye diseases
eye close up
ONS-5010 is injected into the eye for the treatment of wet age-related macular degeneration and other retina diseases

Outlook Therapeutics (NASDAQ:OTLK) continued to rocket higher Monday morning after Oppenheimer initiated coverage Thursday with an Outperform rating and a $12 per share price target.

Shares of the clinical-stage biopharmaceutical company jumped another 36% to $2.87, more than triple its Wednesday close.

Analysts at Oppenheimer saw immense potential in the development of the Cranbury, New Jersey company’s ONS-5010 treatment, a monoclonal antibody, or mAb, for various eye diseases.

READ: Outlook Therapeutics initiated with an Outperform rating, $12 price target at Oppenheimer

ONS-5010 is a proprietary formulation of bevacizumab, a drug sold under the brand name Avastin, injected into the eye for the treatment of wet age-related macular degeneration (AMD), and other retina diseases. AMD manifests itself through the appearance of abnormal blood vessels under the retina growing toward the macula, obstructing vision.

“Assuming a late 2021-22 FDA approval in wet AMD that we view as low-risk, ONS-5010 stands to take Avastin's approximately 50% unit share in this multibillion-dollar indication as physicians and payors adopt it,” wrote Oppenheimer analysts Leland Gershell and Aryeh Gold in a note to clients.

Avastin is sold by Genetech Inc as a cancer drug, but is used off-label to treat certain eye diseases. However, it’s not without risk. Off-label use of Avastin is currently estimated to account for approximately 50% of all wet age-related macular degeneration prescriptions in the US.

That’s where ONS-5010 comes in. If it were to earn FDA approval, the use of compounded Avastin would become illegal, the analysts wrote.

In an expeditious registration program informed by FDA input, ONS-5010 is being evaluated in two Phase 3 non-inferiority trials versus Lucentis, another wet AMD drug, on visual acuity, from which topline data will be reported in the first quarter of 2020 and third quarter of 2020.

“Outlook will maximize ONS-5010's opportunity to subsume Avastin's place in the wet AMD treatment paradigm, including intelligent pricing, payor collaboration, and an eventual pre-filled syringe,” wrote the analysts.

–This story was updated to attribute statements regarding ONS-5010's potential FDA approval to the Oppenheimer analysts–

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

View full OTLK profile View Profile

Related Articles

Cameron Durrant
March 05 2019
A goal is to improve the safety of CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas
January 15 2019
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
genedrive device
May 23 2019
Here we take a closer look at Genedrive PLC (LON:GDR)

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use